- Trials with a EudraCT protocol (251)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
251 result(s) found for: Ambulatory care.
Displaying page 1 of 13.
EudraCT Number: 2022-003126-42 | Sponsor Protocol Number: DT-DEC01-DMD-CT-Phase1/2 | Start Date*: 2023-12-12 |
Sponsor Name:Dystrogen Therapeutics Technology Polska Spółka z Ograniczoną Odpowiedzialnością | ||
Full Title: A Phase 1/2, Open-Label, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of DT-DEC01 Therapy in Patients with Duchenne Muscular Dystrophy | ||
Medical condition: Duchenne muscular dystrophy (DMD) is the most common inherited neuromuscular disease that mostly affects boys. DMD is a type of X-linked disease caused by a mutation of the gene at the Xp21 locus t... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006928-18 | Sponsor Protocol Number: 06/Q0603/57 | Start Date*: 2007-04-25 | |||||||||||
Sponsor Name:Barts and The London NHS Trust | |||||||||||||
Full Title: Randomised trial of Prontosan wound gel for prevention of exit site infection in peritoneal dialysis patients | |||||||||||||
Medical condition: Peritoneal dialysis patients and their peritoneal dialysis catheter exit site care. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004809-58 | Sponsor Protocol Number: HEBRO-001 | Start Date*: 2019-04-04 | |||||||||||
Sponsor Name:Institute for study, research, education and therapy of vascular, heart, brain and kidney nosologies (I.N.A.K.E.N) | |||||||||||||
Full Title: Comparative study of eplerenone-based treatment strategy versus irbesartan-based blood pressure lowering in obese hypertensive patients (HEBRO Study) | |||||||||||||
Medical condition: Primary Hypertension and Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000509-54 | Sponsor Protocol Number: MB121-008 | Start Date*: 2012-09-12 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy of BMS-823778 in Overweight and Obese Subjects with Inadequately Cont... | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005911-27 | Sponsor Protocol Number: S64445 | Start Date*: 2021-03-17 |
Sponsor Name:KU Leuven | ||
Full Title: The DAWN antivirals trial: the efficacy of antivirals for COVID-19 infections presenting to ambulatory care: a randomized controlled trial. | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-003867-76 | Sponsor Protocol Number: RRK4249 | Start Date*: 2013-11-07 | |||||||||||||||||||||||||||||||
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | |||||||||||||||||||||||||||||||||
Full Title: A prospective, randomised controlled trial to determine the safety and efficacy of steroid impregnated tape compared to standard therapy with silver nitrate in the treatment of over-granulating per... | |||||||||||||||||||||||||||||||||
Medical condition: Over-granulation of peritoneal dialysis exit site in patients with End Stage Renal Failure | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000699-39 | Sponsor Protocol Number: FGCL-3019-094 | Start Date*: 2021-11-04 | |||||||||||
Sponsor Name:FibroGen, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Ambulatory Subjects with Duchenne Muscular Dystrophy (DMD) | |||||||||||||
Medical condition: Ambulatory Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) AT (Prematurely Ended) NL (Completed) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005274-30 | Sponsor Protocol Number: UCL_2011_DIDo | Start Date*: 2012-08-27 | |||||||||||
Sponsor Name:Université catholique de Louvain | |||||||||||||
Full Title: Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on incremental Peritoneal Dialysis therapy: the DIDo study | |||||||||||||
Medical condition: Patients with chronic renal failure who are starting a Continuous Ambulatory Peritoneal Dialysis (CAPD) as first line dialyse. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000869-38 | Sponsor Protocol Number: VGSKAS-12916 | Start Date*: 2008-06-02 |
Sponsor Name:Skaraborg Hospital | ||
Full Title: Impact of Losartan in hypertensive men with obstructive sleep apnea | ||
Medical condition: Hypertension and obstructive sleep apnea (OSA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002890-31 | Sponsor Protocol Number: Pregab1 | Start Date*: 2006-08-25 |
Sponsor Name:Dept. of Anaesthesia, Medical University of Vienna | ||
Full Title: Does Pregabalin reduce preoperative anxiety: a placebo controlled study | ||
Medical condition: Patients should receive Pregabalin or placebo as premedication one hour before ambulatory elective surgery. After this they have to assess their anxiety and pain with Visual Analog Scale (VAS) for ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003987-35 | Sponsor Protocol Number: Metamizole001 | Start Date*: 2015-11-10 |
Sponsor Name:JESSA Hospital | ||
Full Title: Metamizole versus NSAID at home after ambulatory surgery: a double-blind randomized controlled trial | ||
Medical condition: Pain after ambulatory surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002545-32 | Sponsor Protocol Number: CR0002 | Start Date*: 2019-11-06 | |||||||||||
Sponsor Name:Ablative Solutions, Inc | |||||||||||||
Full Title: A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension. | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Ongoing) BE (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000269-34 | Sponsor Protocol Number: GC2010 | Start Date*: 2021-03-20 | ||||||||||||||||||||||||||
Sponsor Name:Grifols Therapeutics LLC | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) versus Placebo in Asymptomatic Ambulatory... | ||||||||||||||||||||||||||||
Medical condition: Subjects with laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative PCR (reverse transcriptase [RT]-PCR) that are asymptomathic | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004553-41 | Sponsor Protocol Number: UX001-CL203 | Start Date*: 2017-01-05 | ||||||||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||||||||||||||||||
Full Title: A Phase 2 Open-label study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER) Tablets in GNE Myopathy (GNEM) (also known as Hereditary Inclusion Body Myopathy (HIBM)) patients wit... | ||||||||||||||||||
Medical condition: GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), Distal Myopathy with Rimmed Vacuoles (DMRV), Nonaka’s disease, or quadriceps sparing myopathy (QSM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004995-13 | Sponsor Protocol Number: 38372 | Start Date*: 2012-02-09 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Endovascular renal sympathetic denervation versus spironolactone for treatment-resistant hypertension: a randomized, multicentric study | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002779-32 | Sponsor Protocol Number: PREEMTIVE | Start Date*: 2019-12-26 |
Sponsor Name:BERTA CASTELLANO PAULIS | ||
Full Title: “Pre-emptive analgesia with Ibuprofen in outpatient laparoscopic cholecystectomy. Recovery Quality ” | ||
Medical condition: AMBULATORY LAPAROSCOPIC COLECISTECTOMY | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001740-26 | Sponsor Protocol Number: ATOMIC2 | Start Date*: 2020-05-05 | ||||||||||||||||
Sponsor Name:University of Oxford, Clinical Trials and Research Governance | ||||||||||||||||||
Full Title: A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2) | ||||||||||||||||||
Medical condition: COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001630-21 | Sponsor Protocol Number: BAY59-7939/39039039STM4001/18262 | Start Date*: 2015-12-15 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism | |||||||||||||
Medical condition: Venous thromboembolism (VTE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000890-10 | Sponsor Protocol Number: MP0420-CP302 | Start Date*: 2021-05-03 | |||||||||||
Sponsor Name:Molecular Partners AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19 | |||||||||||||
Medical condition: Symptomatic COVID-19 in ambulatory patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003739-20 | Sponsor Protocol Number: ADS-AMT-PD302 | Start Date*: 2015-04-23 | |||||||||||
Sponsor Name:Adamas Pharmaceuticals, Inc. | |||||||||||||
Full Title: Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia | |||||||||||||
Medical condition: Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
